Commodore discloses 7.1% Century Therapeutics (NASDAQ: IPSC) stake

Rhea-AI Filing Summary

Century Therapeutics, Inc. (IPSC) received a Schedule 13G filing from Commodore Capital and related parties. The filing reports beneficial ownership of 13,043,478 shares of Century Therapeutics common stock, representing 7.1% of the outstanding class.

The position consists of 8,695,652 shares of common stock plus 4,347,826 additional shares underlying a warrant. Ownership percentages are based on 179,337,686 shares outstanding as of January 9, 2026, plus the warrant shares. Commodore Capital LP, Commodore Capital Master LP, and individuals Robert Egen Atkinson and Michael Kramarz share voting and dispositive power over the reported shares.

The filers certify that the securities were not acquired and are not held for the purpose of changing or influencing control of Century Therapeutics, which is why the stake is reported on a Schedule 13G instead of a control‑oriented Schedule 13D.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Century Therapeutics, Inc.

(Name of Issuer)

Common Stock, par value $0.0001 per share

(Title of Class of Securities)

15673T100

(CUSIP Number)

01/09/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 15673T100

1

Names of Reporting Persons

Commodore Capital LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 13,043,478.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 13,043,478.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,043,478.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.1 %

12

Type of Reporting Person (See Instructions)

PN, IA

SCHEDULE 13G

CUSIP No. 15673T100

1

Names of Reporting Persons

Commodore Capital Master LP

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

CAYMAN ISLANDS

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 13,043,478.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 13,043,478.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,043,478.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.1 %

12

Type of Reporting Person (See Instructions)

PN

SCHEDULE 13G

CUSIP No. 15673T100

1

Names of Reporting Persons

Robert Egen Atkinson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 13,043,478.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 13,043,478.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,043,478.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.1 %

12

Type of Reporting Person (See Instructions)

HC, IN

SCHEDULE 13G

CUSIP No. 15673T100

1

Names of Reporting Persons

Michael Kramarz

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 13,043,478.00
7	Sole Dispositive Power 0.00
8	Shared Dispositive Power 13,043,478.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

13,043,478.00

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

7.1 %

12

Type of Reporting Person (See Instructions)

IN, HC

SCHEDULE 13G

Item 1.
(a)	Name of issuer: Century Therapeutics, Inc.
(b)	Address of issuer's principal executive offices: 25 North 38th Street, 11th Floor, Philadelphia, PENNSYLVANIA, 19104.
Item 2.
(a)	Name of person filing: Commodore Capital LP Commodore Capital Master LP Robert Egen Atkinson Michael Kramarz Each a "Filer."
(b)	Address or principal business office or, if none, residence: The address for Commodore Capital LP, Robert Egen Atkinson, and Michael Kramarz is 444 Madison Avenue, Floor 35, New York, NY 10022. The address for Commodore Capital Master LP is c/o Maples Corporate Services Limited, Ugland House, South Church Street, PO Box 309, Grand Cayman KY1-1104, Cayman Islands.
(c)	Citizenship: See Item 4 of the cover page for each Filer.
(d)	Title of class of securities: Common Stock, par value $0.0001 per share
(e)	CUSIP No.: 15673T100
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: See Item 9 of the cover page for each Filer. This report on Schedule 13G is being filed by Commodore Capital LP (the "Firm"), Commodore Capital Master LP ("Commodore Master"), Michael Kramarz, and Robert Egen Atkinson. The Firm is the investment manager to Commodore Master. As of January 9, 2026, the Firm may be deemed to beneficially own an aggregate of 13,043,478 shares Common Stock, par value $0.0001 per share (the "Common Stock"), consisting of (i) 8,695,652 shares of the Common Stock and (ii) 4,347,826 shares of Common Stock underlying a warrant of Century Therapeutics, Inc. (the "Issuer"). The Firm, as the investment manager to Commodore Master, may be deemed to beneficially own these securities. Michael Kramarz and Robert Egen Atkinson are the managing partners of the Firm and exercise investment discretion with respect to these securities. Ownership percentages are based on 179,337,686 shares of Common Stock outstanding on January 9, 2026, as reported directly by the Issuer to the Firm, plus 4,347,826 shares of Common Stock which the Filers may acquire upon the exercise of the warrants.
(b)	Percent of class: See Item 11 of the cover page for each Filer.
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: See Item 5 of the cover page for each Filer.
	(ii) Shared power to vote or to direct the vote: See Item 6 of the cover page for each Filer.
	(iii) Sole power to dispose or to direct the disposition of: See Item 7 of the cover page for each Filer.
	(iv) Shared power to dispose or to direct the disposition of: See Item 8 of the cover page for each Filer.
Item 5.	Ownership of 5 Percent or Less of a Class.
	Not Applicable
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	Not Applicable
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	Not Applicable
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Commodore Capital LP

Signature:	Michael Kramarz
Name/Title:	Managing Partner
Date:	01/16/2026

Commodore Capital Master LP

Signature:	Michael Kramarz
Name/Title:	Authorized Signatory
Date:	01/16/2026

Robert Egen Atkinson

Signature:	Robert Egen Atkinson
Name/Title:	Authorized Signatory
Date:	01/16/2026

Michael Kramarz

Signature:	Michael Kramarz
Name/Title:	Authorized Signatory
Date:	01/16/2026

Exhibit Information

Exhibit 1: Joint Filing Agreement

FAQ

What stake in Century Therapeutics (IPSC) does Commodore Capital report on this Schedule 13G?

The filing reports that the filers beneficially own 13,043,478 shares of Century Therapeutics common stock, representing 7.1% of the outstanding class.

How is the 13,043,478-share Century Therapeutics (IPSC) position composed?

The reported position consists of 8,695,652 shares of common stock plus 4,347,826 shares of common stock underlying a warrant held by the filers.

Who are the reporting persons on the Century Therapeutics (IPSC) Schedule 13G?

The reporting persons are Commodore Capital LP, Commodore Capital Master LP, and individuals Robert Egen Atkinson and Michael Kramarz, each listed as a separate filer.

What ownership percentage in Century Therapeutics (IPSC) does the 13,043,478 shares represent?

The filing states that the 13,043,478 shares represent 7.1% of the class of Century Therapeutics common stock, based on the shares outstanding plus warrant shares referenced in the document.

Does the Schedule 13G state an intent to influence control of Century Therapeutics (IPSC)?

No. The filers certify that the securities were not acquired and are not held for the purpose or effect of changing or influencing control of Century Therapeutics, consistent with a passive Schedule 13G filing.

As of what date is Commodore Capital’s Century Therapeutics (IPSC) ownership calculated?

The ownership figures are stated as of January 9, 2026, when 179,337,686 shares of common stock were outstanding, plus 4,347,826 warrant shares the filers may acquire.